Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following November 2025 newly approved drugs will be reviewed:
a. Blujepa - Antibiotics - N/A
b. Brekiya - Migraine Agents - N/A
c. Dawnzera - Corticosteroids-Immune Modulators - Hereditary Angiodema Agents
d. escitalopram - Antidepressants and Non-opioid Pain Syndrome Agents - Selective Serotonin Reuptake Inhibitors
e. Exxua - Antidepressants and Non-opioid Pain Syndrome Agents - N/A
f. Leqembi IQLIK - Alzheimers Agents - N/A
g. ustekinumab-ttwe - Targeted Immunomodulatory Biologics - Interleukin 23
h. Wayrilz - Hematological Agents - Platelets
i. Zurnai - Alcohol Deterrants-Narcotic Antagonists - Narcotic Antagonists
j. Phyrago - Oncological Agents - Chronic Myelogenous Leukemia
k. Inluriyo - Breast Cancer Agents - Estrogen Receptor Antagonist
l. Enbumyst - Diuretics - N/A
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9404.
Pre-quotation teleconference is on October 15, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.